Eric T. Wong
YOU?
Author Swipe
View article: Dose-enhanced vs standard TTFields for first recurrence of glioblastoma. A randomized phase 2 clinical trial
Dose-enhanced vs standard TTFields for first recurrence of glioblastoma. A randomized phase 2 clinical trial Open
Background Studies suggest that high intensities of tumor treating fields (TTFields) correlate with prolonged survival in newly diagnosed glioblastoma. However, no randomized clinical studies have tested different doses of TTFields, and th…
View article: Feedforward miR-181d degradation modulates population variance of methyl-guanine methyl transferase and temozolomide resistance
Feedforward miR-181d degradation modulates population variance of methyl-guanine methyl transferase and temozolomide resistance Open
Intratumoral heterogeneity plays a pivotal role in cancer evolution, providing the substrate for adaptation to selective pressures, including chemotherapy treatment. Here, we demonstrate that miR-181d modulates variability in methyl-guanin…
View article: DNAR-04. Variance in Methyl-guanine methyl transferase (MGMT) expression as a defining feature of intra-tumoral heterogeneity that contribute to acquired temozolomide resistance in glioblastoma
DNAR-04. Variance in Methyl-guanine methyl transferase (MGMT) expression as a defining feature of intra-tumoral heterogeneity that contribute to acquired temozolomide resistance in glioblastoma Open
BACKGROUND The concepts of mean and variance serve complementary roles in biological research. While the former captures the central tendencies of a trait in populations, the latter defines the degree of spread or dispersion of the data po…
View article: RADT-70. WHITE AND GRAY MATTER DIFFERENTIATION IMPACTS DISTRIBUTION OF TUMOR TREATING FIELDS
RADT-70. WHITE AND GRAY MATTER DIFFERENTIATION IMPACTS DISTRIBUTION OF TUMOR TREATING FIELDS Open
BACKGROUND Tumor Treating Fields (TTFields) are an established adjuvant therapy for glioblastoma patients in combination with conventional surgery, radiation and chemotherapy. To model TTFields inside the brain, a key point of debate cente…
View article: DNAR-03. ONC201 synergizes with concurrent temozolomide-radiotherapy against newly diagnosed glioblastomas
DNAR-03. ONC201 synergizes with concurrent temozolomide-radiotherapy against newly diagnosed glioblastomas Open
BACKGROUND Glioblastoma, the most common form of adult primary brain cancer, remains a lethal disease with therapeutic options limited by the blood-brain barrier (BBB). ONC201 (also known as TIC10) is a first-in-class, BBB penetrant imipri…
View article: RADT-39. FLAIR EXTENDING BEYOND A QUADRANT (FEQ) OF THE CEREBRUM AS AN IMAGING BIOMARKER FOR STUDIES OF ACUTE RADIATION EFFECTS IN POST-RADIOSURGERY BRAIN METASTASIS PATIENTS
RADT-39. FLAIR EXTENDING BEYOND A QUADRANT (FEQ) OF THE CEREBRUM AS AN IMAGING BIOMARKER FOR STUDIES OF ACUTE RADIATION EFFECTS IN POST-RADIOSURGERY BRAIN METASTASIS PATIENTS Open
INTRODUCTION Significant variability exists in the use of corticosteroids for treating adverse radiation effects (ARE) after stereotactic radiosurgery (SRS) of brain metastasis (BM). Here, we assess the reliability of a quadrant-based magn…
View article: Medical comorbidities prognosticate survival in glioblastoma
Medical comorbidities prognosticate survival in glioblastoma Open
View article: Case Report: Recurrent High-Risk Neuroblastoma in an Adult Woman 28 Years Following Curative Treatment
Case Report: Recurrent High-Risk Neuroblastoma in an Adult Woman 28 Years Following Curative Treatment Open
An adult woman with a remote history of childhood neuroblastoma at age two presented to the hospital with spinal cord compression. She was ultimately diagnosed with metastatic neuroblastoma 28 years following her initial diagnosis. The pat…
View article: Enabling CAR-T Cell Immunotherapy in Glioblastoma by Modifying Tumor Microenvironment via Oncolytic Adenovirus Encoding Bispecific T Cell Engager
Enabling CAR-T Cell Immunotherapy in Glioblastoma by Modifying Tumor Microenvironment via Oncolytic Adenovirus Encoding Bispecific T Cell Engager Open
Recent clinical trials show that CAR-T cell therapies can initially blunt tumor growth in glioblastoma (GBM) patients. However, the tumor microenvironment activates mechanisms that inhibit tumor-killing potential of the CAR-T cells and lim…
View article: Acquired resistance to molecularly targeted therapies for cancer
Acquired resistance to molecularly targeted therapies for cancer Open
Acquired resistance to molecularly targeted therapies remains a formidable challenge in the treatment of cancer, despite significant advancements over the last several decades. We critically evaluate the evolving landscape of resistance me…
View article: Rehabilitation after bone marrow transplant compared with usual care to improve patient outcomes (REBOOT): protocol for a randomised controlled trial
Rehabilitation after bone marrow transplant compared with usual care to improve patient outcomes (REBOOT): protocol for a randomised controlled trial Open
View article: Worldwide Innovative Network (WIN) Consortium in Personalized Cancer Medicine: Bringing next-generation precision oncology to patients
Worldwide Innovative Network (WIN) Consortium in Personalized Cancer Medicine: Bringing next-generation precision oncology to patients Open
The human genome project ushered in a genomic medicine era that was largely unimaginable three decades ago. Discoveries of druggable cancer drivers enabled biomarker-driven gene- and immune-targeted therapy and transformed cancer treatment…
View article: Hydrogel and scalp/skin conductivities impact dose from tumor treating fields
Hydrogel and scalp/skin conductivities impact dose from tumor treating fields Open
Purpose Tumor Treating Fields (TTFields) are delivered by transducer arrays applied to scalp or body surface for treatment of multiple malignancies. Dermatologic complications are thought to be related to hydrogel situated between the elec…
View article: Effects of craniectomy defect on tumor-treating fields
Effects of craniectomy defect on tumor-treating fields Open
Background Tumor-treating fields (TTFields) are alternating electric fields approved for the treatment of glioblastoma. They must penetrate through the skull to reach the gross tumor volume (GTV) in the brain. Since the skull is an attenua…
View article: The natural history of neurolymphomatosis
The natural history of neurolymphomatosis Open
View article: Shorting vorasidenib for IDH mutant low-grade glioma
Shorting vorasidenib for IDH mutant low-grade glioma Open
View article: Phase 1b/2 study of orally administered pexidartinib in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma
Phase 1b/2 study of orally administered pexidartinib in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma Open
Background Glioblastoma (GBM) has a median survival of <2 years. Pexidartinib (PLX3397) is a small-molecule inhibitor of CSF1R, KIT, and oncogenic FTL3, which are implicated in GBM treatment resistance. Results from glioma models indica…
View article: Directionally non-rotating electric field therapy delivered through implanted electrodes as a glioblastoma treatment platform: A proof-of-principle study
Directionally non-rotating electric field therapy delivered through implanted electrodes as a glioblastoma treatment platform: A proof-of-principle study Open
Background While directionally rotating tumor-treating fields (TTF) therapy has garnered considerable clinical interest in recent years, there has been comparatively less focus on directionally non-rotating electric field therapy (dnEFT). …
View article: Tumor-treating fields dosimetry in glioblastoma: Insights into treatment planning, optimization, and dose–response relationships
Tumor-treating fields dosimetry in glioblastoma: Insights into treatment planning, optimization, and dose–response relationships Open
Tumor-treating fields (TTFields) are currently a Category 1A treatment recommendation by the US National Comprehensive Cancer Center for patients with newly diagnosed glioblastoma. Although the mechanism of action of TTFields has been part…
View article: Autologous Cell Immunotherapy (IGV-001) with IGF-1R Antisense Oligonucleotide in Newly Diagnosed Glioblastoma Patients
Autologous Cell Immunotherapy (IGV-001) with IGF-1R Antisense Oligonucleotide in Newly Diagnosed Glioblastoma Patients Open
Standard-of-care first-line therapy for patients with newly diagnosed glioblastoma (ndGBM) is maximal safe surgical resection, then concurrent radiotherapy and temozolomide, followed by maintenance temozolomide. IGV-001, the first product …
View article: INNV-31. ADOPTING TUMOR TREATING FIELDS (TTFIELDS) THERAPY FOR GLIOBLASTOMA AND OTHER SOLID CANCERS: CHALLENGES AND OPPORTUNITIES
INNV-31. ADOPTING TUMOR TREATING FIELDS (TTFIELDS) THERAPY FOR GLIOBLASTOMA AND OTHER SOLID CANCERS: CHALLENGES AND OPPORTUNITIES Open
Tumor Treating Fields (TTFields) are alternating electric fields generated by a wearable medical device (NovoTTF-200A), delivered to the tumor target by arrays placed on the skin. These fields have multiple biological effects on tumor cell…
View article: RTID-08. A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 2B STUDY OF IGV-001, AN AUTOLOGOUS CELL IMMUNOTHERAPY WITH ANTISENSE OLIGO IMV-001 TARGETING IGF-1R, VS PLACEBO, IN NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS
RTID-08. A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 2B STUDY OF IGV-001, AN AUTOLOGOUS CELL IMMUNOTHERAPY WITH ANTISENSE OLIGO IMV-001 TARGETING IGF-1R, VS PLACEBO, IN NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS Open
Glioblastoma (GBM) is the most common primary brain malignancy in adults. Standard of care (SOC) for suspected GBM begins with maximal safe resection followed by adjuvant radiotherapy and temozolomide, and maintenance temozolomide. Imvax h…
View article: NCMP-29. THE NATURAL HISTORY OF NEUROLYMPHOMATOSIS
NCMP-29. THE NATURAL HISTORY OF NEUROLYMPHOMATOSIS Open
Neurolymphomatosis is a rare lymphoid malignancy of the peripheral nervous system. Patients suffer from debilitating neurological deficits due to lymphoma invasion into one or more peripheral nerves and the natural history of this disease …
View article: Body Fluids Modulate Propagation of Tumor Treating Fields
Body Fluids Modulate Propagation of Tumor Treating Fields Open
Tumor treating fields (TTFields) are nonionizing alternating electric fields that have anticancer properties. After the initial approval for use in patients with recurrent glioblastoma in 2011 and newly diagnosed glioblastomas in 2015, the…
View article: Lewy body disease as a potential negative outcome modifier of glioblastoma treatment: a case report
Lewy body disease as a potential negative outcome modifier of glioblastoma treatment: a case report Open
View article: How robust are the data in vorasidenib for isocitrate dehydrogenase-1 or isocitrate dehydrogenase-2 mutant low-grade glioma?
How robust are the data in vorasidenib for isocitrate dehydrogenase-1 or isocitrate dehydrogenase-2 mutant low-grade glioma? Open
Dear Editor, Mellinghoff et al.[1] conducted a double-blinded randomized study INDIGO investigating the effect of brain-penetrant vorasidenib against low-grade gliomas with mutated isocitrate dehydrogenase (IDH-1) and IDH-2. This is based …
View article: Supplemental Tables 1-3 from A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients
Supplemental Tables 1-3 from A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients Open
Supplemental Tables 1-3. Supplementary Table 1: Correlations in the vandetanib/RT/TMZ arm between best radiographic responses with pre-treatment and on-treatment changes in blood biomarkers. Supplementary Table 2: Correlations in the vande…
View article: Supplemental Figure from A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients
Supplemental Figure from A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients Open
Supplemental Figure: Mean plasma concentrations of vandetanib.
View article: Supplemental Tables 1-3 from A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients
Supplemental Tables 1-3 from A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients Open
Supplemental Tables 1-3. Supplementary Table 1: Correlations in the vandetanib/RT/TMZ arm between best radiographic responses with pre-treatment and on-treatment changes in blood biomarkers. Supplementary Table 2: Correlations in the vande…
View article: Data from A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients
Data from A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients Open
Purpose: Vandetanib, a tyrosine kinase inhibitor of KDR (VEGFR2), EGFR, and RET, may enhance sensitivity to chemotherapy and radiation. We conducted a randomized, noncomparative, phase II study of radiation (RT) and temozolomide wit…